Obesity (Assessment)
Health History
Nurses need to approach patients with obesity with the same respectful, courteous, and empathetic behavior that they extend to patients without obesity. Confronting their own attitudes and beliefs about patients with obesity may help mitigate unconscious biases. For instance, using patient-first language for all patients, including those with obesity, can be an effective way to dispel bias. By referencing the patient with obesity, the nurse is effectively noting that the patient, not the condition, is the central point of concern. On the other hand, referencing the obese patient tends to define the people by having obesity, which can lead to subliminal impressions that the patient is somehow responsible for having obesity. Research reports that many patients refrain from scheduling appointments with their health care providers, including nurses, due to perceived or experienced negative attitudes that patients with obesity are indulgent, lazy, and lack willpower (Fruh et al., 2021).
Patients with obesity are assessed for recent increases or decreases in body weight. Analyzing the cues of recent weight loss or gain helps determine if these changes in weight might be secondary to a disease process. Other useful health history information to gather includes how long the patient has had obesity (e.g., since childhood, since a pregnancy) and whether there is a family history of obesity. Patterns of weight loss over time and prior successful or unsuccessful weight loss strategies should be analyzed. A history of exercise patterns and dietary patterns (see Chapter 4 for discussion of nutritional assessment) is also assessed. Some patients report sleep pattern disturbances (e.g., difficulty falling asleep, difficulty staying asleep); therefore, typical sleeping habits are evaluated. Some patients who quit smoking report significant weight gain after smoking cessation is achieved; consequently, the patient’s smoking status is also determined (Perreault, 2023).
Some patients may be prescribed medications that can exacerbate weight gain or cause new weight gain (Chart 43-1). A history of weight gain that parallels the time frame of commencing treatment with specific medications may suggest the medication is a factor in weight gain. In some instances, prescription medication dosages may be adjusted or another medication may be prescribed. For instance, patients with type 2 diabetes and obesity may reap the dual benefits of achieving better glycemic control and weight loss with certain prescription drugs like metformin, semaglutide, and tirzepatide (Bays et al., 2022). See Chart 43-2.
Pharmacology
Select Medications That Affect Body Weight
Many medications prescribed to treat a variety of chronic diseases and disorders have the side effect of weight gain, whereas others are associated with weight loss.
Medications Associated With Weight Gain
Anticonvulsant medications (e.g., gabapentin, valproic acid)
Antidepressant medications
•Selective serotonin reuptake inhibitors (SSRIs) (Note: These are associated with early weight loss followed by gain within 6 months in some patients; e.g., citalopram, fluvoxamine, paroxetine, sertraline.)
•Tricyclic antidepressant agents (e.g., amitriptyline, clomipramine, doxepin, imipramine)
Antihistamines (e.g., cetirizine, diphenhydramine)
Antihypertensive medications
•α-Blockers (e.g., terazosin)
•β-Blockers (e.g., atenolol, metoprolol, atenolol)
•Dihydropyridine calcium channel blockers (e.g., amlodipine, felodipine, nifedipine)
Antipsychotic medications (e.g., chlorpromazine, olanzapine, risperidone)
Diabetes medications
•Insulins (e.g., insulin aspart, insulin glulisine, insulin lispro)
•Meglitinides (e.g., nateglinide, repaglinide)
•Sulfonylureas (e.g., glimepiride, glipizide, glyburide, tolbutamide)
•Thiazolidinedione (e.g., pioglitazone)
Hormones
•Corticosteroids (e.g., prednisone, budesonide, methylprednisolone)
•Hormonal contraceptives (e.g., medroxyprogesterone)
Mood stabilizers (e.g., lithium)
Medications Associated With Weight Loss
Anticonvulsant medications (e.g., topiramate)
Antidepressant medications (e.g., bupropion, venlafaxine)
Diabetes medications
•Biguanide (e.g., metformin)
•Glucagonlike peptide 1 (GLP-1) agonists (e.g., liraglutide, semaglutide)
•Glucose-dependent insulinotropic polypeptide (e.g., tirzepatide)
Adapted from Comerford & Durkin (2024); Dietz (2023); VA/DoD Clinical Practice Guideline (2020a, 2020b).
Physical Assessment
Patient’s height and weight are measured to determine the body mass index. The BMI is the most commonly used first measure to screen a patient for obesity; this is based on a ratio of body weight in kilograms and height in meters (see Chapter 4, Table 4-1). Using this method, patients are considered overweight with a BMI of 25 to 29.9 kg/m2, while those with obesity have a BMI that exceeds 30 kg/m2 (ASMBS, 2023a) (Fig. 43-1; Table 43-1). While the BMI continues to be utilized as the sole screening metric for obesity by many clinicians and insurers, there are concerns about the accuracy of using BMI alone, especially when considering age, race, and ethnicity (American Medical Association [AMA], 2023). In particular, BMI does not differentiate between the body’s composition of fat and lean mass nor does it identify body fat distribution (Rubino et al., 2025). Rather, the BMI should be used in tandem with other measures, such as relative fat mass and body adiposity index (AMA, 2023).
Ethical Dilemma
Who Should Receive a Scarce Drug First?
Case Scenario
You are one of several nurse navigators employed in an outpatient diabetes center. This past week, your office has been deluged with calls from patients who are reporting difficulty getting their prescriptions for semaglutide filled at local pharmacies. A nurse navigator colleague, L.B., shakes their head and says, “This just makes me sick! This drug is meant for patients with diabetes! There would not be a shortage of this drug if people who are fat could just learn to take better care of themselves and diet and exercise like everyone else. They should be prohibited from getting their prescriptions filled when the supply is low so that our patients with diabetes can get it first.” You share L.B.’s frustration about patients with diabetes not being able to get semaglutide but you wonder if L.B.’s proposed solution is equitable.
Discussion
Semaglutide was first developed and approved to treat select patients with type 2 diabetes. More recently, the U.S. Food and Drug Administration (FDA) approved it to also treat select patients with obesity or who are overweight with concomitant cardiovascular disease. Because of their effectiveness in weight loss, the demand for this drug and similar drugs in its class has resulted in significant shortages.
Some people have criticized the drug manufacturers’ marketing campaigns for these drugs, saying that they should have anticipated increased demand, and then also ramped up their supply chains to meet the demand. Others have noted that off-label use of these drugs by patients who are not obese and who wish to lose a few pounds of weight for cosmetic reasons should be better monitored and curtailed (Lupkin, 2024).
Patients with diabetes who take semaglutide and who ration or stop taking the drug will have hyperglycemia, which, if sustained, can result in a host of adverse disorders (e.g., chronic kidney disease, retinopathy; see Chapter 47 for further discussion). However, patients with obesity can also suffer adverse health effects from obesity over time (e.g., risk for certain cancers, osteoarthritis, cardiovascular disease).
Analysis
•Identify the most salient ethical principles that are in conflict in this case (see Chapter 1, Chart 1-5). Patient autonomy, or self-determination, is generally considered the preeminent ethical principle. Can patient autonomy be preserved when resources are scarce?
•Is it just to limit who may receive a drug such as semaglutide when its supply becomes scarce? If so, how can this be accomplished fairly? Should patients with type 2 diabetes receive their prescriptions before patients with obesity? Is this a type of discrimination?
•Is it possible for you to ensure that just and fair decisions are being made for your patients and for the people you serve within your community?
Classification
BMI Range (kg/m2)
Healthy weight
18.5–24.9
Overweight/preobesity
25–29.9
Class I obesity
30–34.9
Class II obesity
35–39.9
Class III obesity
≥40
Diagnostic Evaluation
Providers may request other diagnostic laboratory studies for patients with excess adiposity to screen for clinical obesity. For example, cholesterol and triglycerides levels may be assessed for the patient suspected of cardiovascular disease (see Chapter 24); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels may be assessed in the patient suspected of having nonalcoholic fatty liver disease (Tondt et al., 2023) (see Chapter 44). Obesity is the top risk factor for obstructive sleep apnea (OSA) in males before age 50 (Collop, 2024; Kline, 2023). Patients with obesity and sleep disturbances may undergo diagnostic sleep studies (see Chapter 19). Select diseases and disorders associated with clinical obesity are displayed in Chart 43-3.
In some instances, obesity may be secondary to other diseases or disorders, such as hypothyroidism or Cushing syndrome (see Chapter 46). In those particular cases, the diagnostic workup follows that prescribed for the primary disease or disorder, and when the therapeutic regimen is implemented, the patient may lose weight (Tondt et al., 2023). When obesity is diagnosed, timely interventions can improve glucose and lipid metabolism, reduce blood pressure, improve mobility, and ultimately reduce the onset of comorbidities (Tondt et al., 2023).